tersolisib (Eli Lilly and Company)

Tersolisib (LY3023414) is an orally bioavailable, small-molecule dual inhibitor of phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR), developed by Eli Lilly. It targets all four isoforms of Class I PI3K (alpha, beta, delta, and gamma) as well as mTORC1 and mTORC2. By inhibiting these key components of the PI3K/AKT/mTOR signaling pathway, tersolisib aims to suppress tumor cell proliferation and induce apoptosis in various malignancies, including breast cancer and other solid tumors. Clinical development has primarily focused on its use in combination with other therapies, such as endocrine therapy for hormone receptor-positive, HER2-negative breast cancer, although several trials have been discontinued.

Other names

tersolisib hemihydrate